Viatris Pharmaceuticals Co-Hosts Public Lecture on Generalized Anxiety Disorder (GAD): 'Worried? It Might Be GAD' at the 3rd Annual Meeting of the Japanese Society of Outpatient Psychiatry, June 20 in Yokohama

・Specialists will clearly explain GAD characteristics, diagnosis, and treatment importance.

・Individuals who have experienced GAD will share their personal stories.

・Free participation, also available online.

Viatris Pharmaceuticals LLC (headquarters: Tokyo, President: Kim Suna), the Japanese subsidiary of global healthcare company Viatris Inc. (Nasdaq: VTRS), will co-host a public lecture titled "Worried? It Might Be GAD – Understanding Generalized Anxiety Disorder: Disease Mechanism, Diagnosis, and Treatment" with the 3rd Annual Meeting of the Japanese Society of Outpatient Psychiatry on Saturday, June 20, 2026, at Pacifico Yokohama (Yokohama, Kanagawa Prefecture).

GAD is a disorder characterized by chronic, uncontrollable excessive anxiety and worry about multiple events or activities. In addition to anxiety and worry, it can cause physical symptoms such as sleep disturbance, muscle tension, restlessness, fatigue, irritability, and difficulty concentrating, leading to serious functional impairment in daily life and work (1). According to the World Health Organization (WHO), the lifetime prevalence of GAD in Japan is 2.6% (2), while a recent study using the self-administered questionnaire GAD-7 reported a prevalence of 7.6% for suspected GAD (score ≥10) (3).

However, many cases are dismissed as "personality issues" or "just being a worrier," and appropriate support, including medical consultation, is not sought. In fact, only 30.9% of those who have experienced GAD have received treatment at a medical institution (2).

Until now, no drugs were approved for GAD in Japan, leaving many patients suffering without proper diagnosis or treatment. With the emergence of new treatment options, it is crucial to provide accurate information about GAD in an easy-to-understand manner, encouraging those who have endured symptoms as part of their personality or hesitated to seek help to obtain appropriate treatment through medical consultation.

This public lecture will feature leading psychiatrists who will explain GAD pathology, diagnosis, and treatment in a way accessible to the general public. Additionally, individuals who have experienced GAD will share their stories in a panel discussion, deepening understanding of living with GAD. The lecture is co-hosted with the 3rd Annual Meeting of the Japanese Society of Outpatient Psychiatry, admission is free, and online viewing is available. Pre-registration is recommended, but on-site participation is possible.

This event is part of Viatris's mission to "contribute to a healthier life for everyone at every stage of life," aiming to improve disease understanding and bridge the gap to proper diagnosis and treatment in mental health.

Viatris Pharmaceuticals, as a company providing medicines across a wide range of therapeutic areas including psychiatric and neurological disorders, has contributed to building a society where people suffering from mental health issues such as anxiety and depression can safely connect with healthcare. Through this lecture, we hope to spread correct understanding of GAD and encourage early consultation and treatment.

Event Overview

Name: Worried? It Might Be GAD – Understanding Generalized Anxiety Disorder: Disease Mechanism, Diagnosis, and Treatment

Date & Time: Saturday, June 20, 2026, 10:00–11:45 (Doors open at 9:30)

Venue: Pacifico Yokohama Conference Center, 4th Floor, Room 411+412 (1-1-1 Minato Mirai, Nishi-ku, Yokohama, Kanagawa)

Admission: Free (Venue capacity: 100, first-come, first-served) *Online viewing available

Program (Tentative)

General Chair: Dr. Teruhiko Higuchi, Emeritus Chairman, Japan Depression Center

・Opening Remarks: Dr. Hidenori Akatsuka, Congress President of the 3rd Annual Meeting of the Japanese Society of Outpatient Psychiatry / Chairman and Director, Kanagawa Clinic

・Lecture 1: "Constant Anxiety Might Be a Disease – Understanding Generalized Anxiety Disorder" by Dr. Yasuyuki Inada, Director, Inada Clinic, Medical Corporation Yujinkai

・Lecture 2: "Do You Know Generalized Anxiety Disorder? Diagnosis and Treatment" by Dr. Toshiki Shioiri, Director, Nozomi no Oka Hospital / Emeritus Professor, Gifu University

・Panel Discussion: Moderator: Dr. Teruhiko Higuchi; Panelists: GAD patient, Dr. Yasuyuki Inada, Dr. Toshiki Shioiri

・Closing Remarks: Dr. Teruhiko Higuchi

Organizer: Viatris Pharmaceuticals LLC

Co-organizer: 3rd Annual Meeting of the Japanese Society of Outpatient Psychiatry

Support: Yokohama City Sports and Culture Bureau / Yokohama City Health and Welfare Bureau

Participation/Online Viewing: Please register at https://forms.office.com/r/5Ga6SDLrwr

*Registration without prior notice is possible, but entry may be refused if the venue is full.

[About Generalized Anxiety Disorder]

Generalized Anxiety Disorder (GAD) is a condition characterized by chronic, uncontrollable anxiety and worry about multiple events or activities. In addition to anxiety and worry, it can cause physical symptoms such as sleep disturbance, muscle tension, restlessness, fatigue, irritability, and difficulty concentrating, leading to serious functional impairment in daily life and work.

[About Viatris]

Viatris is a global healthcare company committed to contributing to a healthier life for everyone at every stage of life. With creativity and determination, we meet the needs of patients worldwide. We provide large-scale, sustainable, and effective solutions in all aspects, including new drug development, ensuring stable supply of essential medicines, and pursuing bold innovation. Our company was established to make an impact through a broad, agile portfolio spanning generic medicines, established brand medicines, and innovative medicines in areas of high unmet medical need. Viatris is headquartered in the United States with global centers in Pittsburgh, Pennsylvania; Shanghai, China; and Hyderabad, India. For more information, visit viatris.com, investor.viatris.com, Twitter/LinkedIn/Instagram/YouTube.